Related references
Note: Only part of the references are listed.Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials
R. Bouamar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients
Leszek Pączek
Annals of Transplantation (2013)
The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations
Laure Elens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients
Oliver Boughton et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients
Dan-ying Li et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
Laure Elens et al.
PHARMACOGENOMICS (2013)
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients
Violette M. G. J. Gijsen et al.
PHARMACOGENOMICS (2013)
CYP3A5 Gene Variation Influences Cyclosporine A Metabolite Formation and Renal Cyclosporine Disposition
Songmao Zheng et al.
TRANSPLANTATION (2013)
Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China
Xiang-guang Meng et al.
ACTA PHARMACOLOGICA SINICA (2012)
Pharmacogenetic biomarkers: cytochrome P450 3A5
Iain A. M. MacPhee
CLINICA CHIMICA ACTA (2012)
ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation
Nauras Shuker et al.
CLINICA CHIMICA ACTA (2012)
Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation
Martine De Meyer et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure
Jason Moore et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Pharmacogenetics in Kidney Transplantation Recent Updates and Potential Clinical Applications
Laure Elens et al.
MOLECULAR DIAGNOSIS & THERAPY (2012)
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients
Kelly A. Birdwell et al.
PHARMACOGENETICS AND GENOMICS (2012)
Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study
Arnaud Capron et al.
TRANSPLANT INTERNATIONAL (2012)
Dosing equation for tacrolimus using genetic variants and clinical factors
Chaitali Passey et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens et al.
CLINICAL CHEMISTRY (2011)
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation
Nicolas Picard et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers
Hui-Lin Tang et al.
PHARMACOGENETICS AND GENOMICS (2011)
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients
Laure Elens et al.
PHARMACOGENOMICS (2011)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity
Christoph Metalidis et al.
TRANSPLANTATION (2011)
Immunosuppression: Does One Regimen Fit All?
Ben Sprangers et al.
TRANSPLANTATION (2011)
Deficiency of Either P-Glycoprotein or Breast Cancer Resistance Protein Protect Against Acute Kidney Injury
Miriam Huls et al.
CELL TRANSPLANTATION (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up
J-B Woillard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?
T. van Gelder et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?
Ryuji Kato et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis
Hui-Lin Tang et al.
PHARMACOGENETICS AND GENOMICS (2010)
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation
Arnaud Capron et al.
PHARMACOGENOMICS (2010)
The Pharmacogenetics of Calcineurin Inhibitor-Related Nephrotoxicity
Dennis A. Hesselink et al.
THERAPEUTIC DRUG MONITORING (2010)
Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects
Yong Zeng et al.
ACTA PHARMACOLOGICA SINICA (2009)
Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts
Maarten Naesens et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India
Ranjana Singh et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus
J. S. Chen et al.
TRANSPLANTATION PROCEEDINGS (2009)
Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients
Shigeru Satoh et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients
Xiao-Yan Qiu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
Dennis A. Hesselink et al.
PHARMACOGENETICS AND GENOMICS (2008)
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients
Severine Crettol et al.
PHARMACOGENETICS AND GENOMICS (2008)
Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations
Ningwu Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Association of four DNA polymorphisms with acute rejection after kidney transplantation
Josep Grinyo et al.
TRANSPLANT INTERNATIONAL (2008)
Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients
Stepan Bandur et al.
TRANSPLANTATION (2008)
Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients
P. T. Loh et al.
TRANSPLANTATION PROCEEDINGS (2008)
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide Polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients
D. R. J. Kuypers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury
M. Huls et al.
KIDNEY INTERNATIONAL (2007)
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2007)
Tacrolimus pharmacokinetics and pharmacogenetics:: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms
Robert A. M. Op den Buijsch et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects
Y.-F. Hu et al.
XENOBIOTICA (2007)
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
L. Renders et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates:: Guidelines from an experimental study
V. Haufroid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
Michel Mourad et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2006)
Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements
Salim Fredericks et al.
TRANSPLANTATION (2006)
Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
Jean Nicholas Roy et al.
PHARMACOGENETICS AND GENOMICS (2006)
Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients
Chi Yuen Cheung et al.
PHARMACOGENOMICS (2006)
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids
M Mourad et al.
TRANSPLANTATION (2005)
Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
X Zhang et al.
CLINICAL TRANSPLANTATION (2005)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
LK Kamdem et al.
CLINICAL CHEMISTRY (2005)
Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein
MS Joy et al.
PHARMACOTHERAPY (2005)
Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
H Tada et al.
TRANSPLANTATION PROCEEDINGS (2005)
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation
IA Hauser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians
IAM MacPhee et al.
TRANSPLANTATION (2005)
Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus
Y Zhao et al.
TRANSPLANTATION PROCEEDINGS (2005)
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
D Anglicheau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
V Haufroid et al.
PHARMACOGENETICS (2004)
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism
HX Zheng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic-polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation
M Goto et al.
PHARMACOGENETICS (2004)
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
IAM MacPhee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
In vitro metabolism of cyclosporine A by human kidney CYP3A5
Y Dai et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
N Tsuchiya et al.
TRANSPLANTATION (2004)
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
CE Staatz et al.
CLINICAL PHARMACOKINETICS (2004)
The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients
R Kreutz et al.
PHARMACOGENETICS (2004)
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
E Thervet et al.
TRANSPLANTATION (2003)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects
DI Min et al.
THERAPEUTIC DRUG MONITORING (2003)
Pharmacokinetics of tacrolimus-based combination therapies
NA Undre
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
HX Zheng et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
Medical progress - Strategies to improve long-term outcomes after renal transplantation
M Pascual et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
NADPH-cytochrome P450 oxidoreductase - Structural basis for hydride and electron transfer
PA Hubbard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance
LP Rivory et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Improved graft survival after renal transplantation in the United States, 1988 to 1996.
S Hariharan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
